Related Experiment Videos
[Tumor marker in primary lung cancer]
Kenji Sugio1, Masakazu Sugaya, Takeshi Hanagiri
1Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Japan.
Journal of UOEH
|December 31, 2004
Summary
Serum tumor markers like NSE and CEA aid in lung cancer diagnosis and treatment monitoring. Specific markers are effective for small cell and non-small cell lung cancer, with varying accuracy based on histological type.
Area of Science:
- Oncology
- Biochemistry
Background:
- Serum tumor markers are vital non-invasive tools for malignant tumor diagnosis.
- They are frequently employed for cancer screening and assessing treatment efficacy.
Purpose of the Study:
- To review the clinical utility of serum tumor markers in primary lung cancer.
- To highlight specific markers for different lung cancer subtypes.
Main Methods:
- Literature review of clinical studies on lung cancer tumor markers.
- Analysis of marker effectiveness in small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
Main Results:
- Neuron-specific enolase (NSE) and pro-gastrin-releasing peptide (proGRP) are effective in SCLC.
- Carcinogenic embryonic antigen (CEA), squamous cell carcinoma antigen (SCC), and cytokeratin 19 fragment (CYFRA21-1) are key markers for NSCLC, with at least one positive in 77% of patients.
- CEA and CYFRA21-1 show high positivity in adenocarcinoma, while CYFRA21-1 and SCC are prevalent in squamous cell carcinoma.
Conclusions:
- Serum tumor markers play a significant role in the clinical management of primary lung cancer.
- The choice of marker is dependent on the specific lung cancer subtype and histological characteristics.